All News

Caroline Rhea and Dr. Mueller speak about the steps Doctors can take to help OAB patients, from recognizing the various symptoms and behaviors of a potential OAB patient to the treatment options available for different types of OAB.

Final analysis of a phase III trial shows abiraterone acetate (ZYTIGA) plus prednisone extended overall survival compared to placebo plus prednisone in chemotherapy-naive men with mCRPC.

Recent phase II results point to the efficacy of the prostate cancer agent enzalutamide (XTANDI) when compared with bicalutamide (Casodex).

Whereas best practice policy states that antimicrobial prophylaxis for urologic procedures should be discontinued within 24 hours, extended regimens are common among patients undergoing surgery for urologic cancer and putting them at risk for hospital-acquired Clostridium difficile colitis, say researchers from the University of Washington, Seattle.

Although salvage artificial urinary sphincter implantations are associated with an increased risk of recurrent erosion/infection requiring explantation, excellent long-term success rates can be attained in carefully selected patients, according to a recent study.

Two angiogenesis inhibitors that are widely used in metastatic renal cell carcinoma did not improve survival compared with placebo when used as adjuvant treatment, a new study found.

Men with prostate cancer who meet the criteria for active surveillance and undergo delayed radical prostatectomy after a period of active surveillance do not have a higher risk of adverse pathology compared with men with similar pre-treatment biopsy features who undergo immediate prostatectomy.

In men who take the 5-alpha-reductase inhibitor finasteride (Propecia) for hair loss, published data on its sexual side effects are insufficient to create a safety profile of the drug, according to a recent study.

There appears to be a trend toward third-party patient financing options in the current environment.

A novel optical imaging technology is showing promise as a potential diagnostic tool for renal cell carcinoma.

Urologist Gary M. Kirsh, MD, says it’s time to bid farewell to fee for service and embrace the concept of value-based compensation in medicine.

In this column, Daniel R. Shaffer of the AACU discusses the recent Urology Joint Advocacy Conference and how urology may have helped move the needle on a promising new SGR proposal.

Dr. Rosevear shares his insights in taking the boards. "As far as rites of passage go, taking the urology boards turned out to be relatively benign. There were no hot coals involved. Read more.

Are you ready for value-based compensation? If not, these 6 steps can help you prepare.

Sophisticated, fun, historic, and some say magical. New Orleans is all that and much more, including home to some of the nation’s best dining venues and most famous chefs.

Charles J. Ryan, MD, recently presented the final analysis of the COU-AA-302 study of abiraterone acetate (ZYTIGA) versus placebo.

We have never seen so many changes in coding and billing for any service that would equal the changes we’ve seen for reporting multiple stones in the urinary system. Over the past 3 years, we’ve witnessed multiple opinions and differing payment results.

In this article, I will discuss additional opportunities for urologists to improve the safety of care in their own practices in the context of the National Quality Forum’s best practices.

For the desperate patient with severe symptoms and a contracted, inflamed bladder who has failed standard therapies, cyclosporine A can be an effective treatment and prevent or delay the need for cystectomy and/or urinary diversion.

Long-term cyclosporine A therapy may be an effective treatment option for refractory interstitial cystitis, say researchers from Brazil.

In cases involving a claim that a patient had an unnecessary operation where cancer was suspected but not found, the issues usually are a lack of informed consent and failure to further investigate the condition to get a definitive diagnosis.

Christopher Amling, MD, describes strategies to reduce skeletal-related morbidity, including lifestyle changes, calcium and vitamin D supplementation, and pharmacologic therapy.

An iodine-125 low-dose-rate brachytherapy boost outperformed dose-escalated external beam radiotherapy boost in achieving biochemical progression-free survival in men with unfavorable risk prostate cancer, according to results of a recent multicenter trial.

The major organizations representing urologists are continuing their push for congressional approval of legislation designed to reform the operations of the U.S. Preventive Services Task Force, which in May 2012 recommended against PSA-based screening for prostate cancer.

In his latest blog post, urologist Neal D. Shore, MD, discusses LUGPA's recent expansion to include independent practices of five or more physicians.

Results presented at the EAU Annual Congress bolster the Prolaris test’s efficacy in determining disease aggressiveness.

Penile transplant surgery, performed successfully for the first time in South Africa, is technically feasible and has potential clinical applications in the United States, according two leading U.S. urologists.

Other highly read UT articles this month include a large comparison of robotic and open RP, answers to your questions about coding for prostate biopsy, and several studies about risks for low and high T.